---
document_datetime: 2025-12-02 04:49:55
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/norvir.html
document_name: norvir.html
version: success
processing_time: 0.1260965
conversion_datetime: 2025-12-23 23:44:15.946869
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Norvir

[RSS](/en/individual-human-medicine.xml/66236)

##### Authorised

This medicine is authorised for use in the European Union

ritonavir Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Norvir](#news-on)
- [More information on Norvir](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Norvir is a medicine used to treat adults and children aged 2 years and older with a human immunodeficiency virus type 1 (HIV-1) infection. HIV-1 is a virus that causes acquired immune deficiency syndrome (AIDS). Norvir is used to enhance the activity of other medicines called protease inhibitors, including atazanavir, fosamprenavir, lopinavir, tipranavir and darunavir.

Norvir contains the active substance ritonavir.

Expand section

Collapse section

## How is Norvir used?

Norvir can only be obtained with a prescription and treatment should be prescribed by a doctor who has experience in treating people with HIV infection.

Norvir is taken by mouth once or twice a day, either as tablets or as a powder that is mixed with food or a liquid. The frequency and dose depend on the protease inhibitor Norvir is given with.

For more information about using Norvir, see the package leaflet or contact your doctor or pharmacist.

## How does Norvir work?

The active substance in Norvir, ritonavir, enhances the activity of other HIV-1 medicines called protease inhibitors. These medicines block an enzyme (a type of protein) of HIV-1 called protease, which the virus needs to make new copies of itself.

When given together with protease inhibitors, ritonavir slows down the rate at which they are broken down in the body. This helps to keep their levels higher in the blood for longer, allowing them to work more effectively against the virus.

Norvir does not cure HIV-1 infections or AIDS. It delays the damage made by the virus to the immune system (the body's natural defences) and the development of infections and diseases associated with AIDS.

## What benefits of Norvir have been shown in studies?

Norvir has been evaluated in studies that looked at its effectiveness when used as a booster for other HIV-1 medicines. Information on these studies can be found in the medicine overviews of these other medicines (atazanavir, fosamprenavir, lopinavir, tipranavir or darunavir).

## What are the risks associated with Norvir?

For the full list of side effects and restrictions with Norvir, see the package leaflet.

Because Norvir is used as a booster for other HIV-1 medicines, its side effects depend on the other medicine taken at the same time (atazanavir, fosamprenavir, lopinavir, tipranavir or darunavir). See the package leaflet provided with the other medicine for information on side effects.

Norvir must not be used in patients who have severe liver problems or in those taking St John's wort (a herbal preparation used to treat depression). It must also not be used with medicines that are broken down in the same way as Norvir, as this may increase their levels in the blood to harmful amounts.

## Why is Norvir authorised in the EU?

In adults and children aged 2 years and older with an HIV-1 infection, Norvir has been shown to increase the blood levels of the other HIV-1 medicines it is used with. The European Medicines Agency therefore decided that Norvir's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Norvir?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Norvir have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Norvir are continuously monitored. Suspected side effects reported with Norvir are carefully evaluated and any necessary action taken to protect patients.

## Other information about Norvir

Norvir received a marketing authorisation valid throughout the EU on 26 August 1996.

Norvir : EPAR - Medicine overview

Reference Number: EMADOC-1829012207-31555

English (EN) (183.75 KB - PDF)

**First published:** 17/11/2009

**Last updated:** 11/11/2025

[View](/en/documents/overview/norvir-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-617)

български (BG) (203.55 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

11/11/2025

[View](/bg/documents/overview/norvir-epar-medicine-overview_bg.pdf)

español (ES) (182.88 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

11/11/2025

[View](/es/documents/overview/norvir-epar-medicine-overview_es.pdf)

čeština (CS) (202.43 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

11/11/2025

[View](/cs/documents/overview/norvir-epar-medicine-overview_cs.pdf)

dansk (DA) (181.8 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

11/11/2025

[View](/da/documents/overview/norvir-epar-medicine-overview_da.pdf)

Deutsch (DE) (185.17 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

11/11/2025

[View](/de/documents/overview/norvir-epar-medicine-overview_de.pdf)

eesti keel (ET) (180.82 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

11/11/2025

[View](/et/documents/overview/norvir-epar-medicine-overview_et.pdf)

ελληνικά (EL) (204.74 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

11/11/2025

[View](/el/documents/overview/norvir-epar-medicine-overview_el.pdf)

français (FR) (183.72 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

11/11/2025

[View](/fr/documents/overview/norvir-epar-medicine-overview_fr.pdf)

hrvatski (HR) (201.89 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

11/11/2025

[View](/hr/documents/overview/norvir-epar-medicine-overview_hr.pdf)

italiano (IT) (181.52 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

11/11/2025

[View](/it/documents/overview/norvir-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (217.65 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

11/11/2025

[View](/lv/documents/overview/norvir-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (202.79 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

11/11/2025

[View](/lt/documents/overview/norvir-epar-medicine-overview_lt.pdf)

magyar (HU) (202.92 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

11/11/2025

[View](/hu/documents/overview/norvir-epar-medicine-overview_hu.pdf)

Malti (MT) (204.15 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

11/11/2025

[View](/mt/documents/overview/norvir-epar-medicine-overview_mt.pdf)

Nederlands (NL) (182.94 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

11/11/2025

[View](/nl/documents/overview/norvir-epar-medicine-overview_nl.pdf)

polski (PL) (207.15 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

11/11/2025

[View](/pl/documents/overview/norvir-epar-medicine-overview_pl.pdf)

português (PT) (184.93 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

11/11/2025

[View](/pt/documents/overview/norvir-epar-medicine-overview_pt.pdf)

română (RO) (201.79 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

11/11/2025

[View](/ro/documents/overview/norvir-epar-medicine-overview_ro.pdf)

slovenčina (SK) (203.03 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

11/11/2025

[View](/sk/documents/overview/norvir-epar-medicine-overview_sk.pdf)

slovenščina (SL) (200.07 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

11/11/2025

[View](/sl/documents/overview/norvir-epar-medicine-overview_sl.pdf)

Suomi (FI) (180.77 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

11/11/2025

[View](/fi/documents/overview/norvir-epar-medicine-overview_fi.pdf)

svenska (SV) (181.64 KB - PDF)

**First published:**

17/11/2009

**Last updated:**

11/11/2025

[View](/sv/documents/overview/norvir-epar-medicine-overview_sv.pdf)

## Product information

Norvir : EPAR - Product information

English (EN) (781.92 KB - PDF)

**First published:** 15/11/2009

**Last updated:** 11/11/2025

[View](/en/documents/product-information/norvir-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-457)

български (BG) (1015.13 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/bg/documents/product-information/norvir-epar-product-information_bg.pdf)

español (ES) (789.67 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/es/documents/product-information/norvir-epar-product-information_es.pdf)

čeština (CS) (912.39 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/cs/documents/product-information/norvir-epar-product-information_cs.pdf)

dansk (DA) (776.64 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/da/documents/product-information/norvir-epar-product-information_da.pdf)

Deutsch (DE) (829.75 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/de/documents/product-information/norvir-epar-product-information_de.pdf)

eesti keel (ET) (775.37 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/et/documents/product-information/norvir-epar-product-information_et.pdf)

ελληνικά (EL) (939.46 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/el/documents/product-information/norvir-epar-product-information_el.pdf)

français (FR) (881.46 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/fr/documents/product-information/norvir-epar-product-information_fr.pdf)

hrvatski (HR) (908.59 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/hr/documents/product-information/norvir-epar-product-information_hr.pdf)

íslenska (IS) (780.16 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/is/documents/product-information/norvir-epar-product-information_is.pdf)

italiano (IT) (861.54 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/it/documents/product-information/norvir-epar-product-information_it.pdf)

latviešu valoda (LV) (906.77 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/lv/documents/product-information/norvir-epar-product-information_lv.pdf)

lietuvių kalba (LT) (932.12 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/lt/documents/product-information/norvir-epar-product-information_lt.pdf)

magyar (HU) (915.29 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/hu/documents/product-information/norvir-epar-product-information_hu.pdf)

Malti (MT) (1.05 MB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/mt/documents/product-information/norvir-epar-product-information_mt.pdf)

Nederlands (NL) (801.86 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/nl/documents/product-information/norvir-epar-product-information_nl.pdf)

norsk (NO) (794.73 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/no/documents/product-information/norvir-epar-product-information_no.pdf)

polski (PL) (928.15 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/pl/documents/product-information/norvir-epar-product-information_pl.pdf)

português (PT) (827.7 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/pt/documents/product-information/norvir-epar-product-information_pt.pdf)

română (RO) (935.17 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/ro/documents/product-information/norvir-epar-product-information_ro.pdf)

slovenčina (SK) (957.61 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/sk/documents/product-information/norvir-epar-product-information_sk.pdf)

slovenščina (SL) (895.77 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/sl/documents/product-information/norvir-epar-product-information_sl.pdf)

Suomi (FI) (810.49 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/fi/documents/product-information/norvir-epar-product-information_fi.pdf)

svenska (SV) (811.9 KB - PDF)

**First published:**

15/11/2009

**Last updated:**

11/11/2025

[View](/sv/documents/product-information/norvir-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000249795 03/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Norvir : EPAR - All authorised presentations

English (EN) (29.97 KB - PDF)

**First published:** 11/01/2007

**Last updated:** 15/03/2019

[View](/en/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-275)

български (BG) (32.75 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/bg/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_bg.pdf)

español (ES) (28.92 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/es/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_es.pdf)

čeština (CS) (29.96 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/cs/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (30.42 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/da/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (29.23 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/de/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (27.99 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/et/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (32.89 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/el/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_el.pdf)

français (FR) (29.07 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/fr/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (28.89 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/hr/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (29.52 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/is/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_is.pdf)

italiano (IT) (28.29 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/it/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (29.4 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/lv/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (30.08 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/lt/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (29.7 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/hu/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (30.04 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/mt/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (27.89 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/nl/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (29.88 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/no/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_no.pdf)

polski (PL) (30.72 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/pl/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_pl.pdf)

português (PT) (29.58 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/pt/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_pt.pdf)

română (RO) (27.99 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/ro/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (29.24 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/sk/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (28.38 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/sl/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (29.64 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/fi/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (28.5 KB - PDF)

**First published:**

11/01/2007

**Last updated:**

15/03/2019

[View](/sv/documents/all-authorised-presentations/norvir-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Norvir Active substance ritonavir International non-proprietary name (INN) or common name ritonavir Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AE03

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1-infected patients (adults and children of two years of age and older).

## Authorisation details

EMA product number EMEA/H/C/000127 Marketing authorisation holder

AbbVie Deutschland GmbH &amp; Co. KG

Knollstrasse 67061 Ludwigshafen Germany

Opinion adopted 23/05/1996 Marketing authorisation issued 25/08/1996 Revision 71

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Norvir : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (145.58 KB - PDF)

**First published:** 11/11/2025

[View](/en/documents/procedural-steps-after/norvir-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Norvir : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (439.18 KB - PDF)

**First published:** 15/11/2009

**Last updated:** 11/11/2025

[View](/en/documents/procedural-steps-after/norvir-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Norvir-VR-0000249795 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMADOC-1700519818-2433345

English (EN) (392.43 KB - PDF)

**First published:** 11/11/2025

[View](/en/documents/variation-report/norvir-vr-0000249795-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Norvir (EMAVR0000249795)

Adopted

Reference Number: EMADOC-1700519818-2433357

English (EN) (156.97 KB - PDF)

**First published:** 19/09/2025

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-norvir-emavr0000249795_en.pdf)

Norvir-H-C-127-P45-0037 : EPAR - Assessment Report

Adopted

Reference Number: EMA/632870/2012EMA/632870/2012

English (EN) (687.45 KB - PDF)

**First published:** 19/06/2013

**Last updated:** 19/06/2013

[View](/en/documents/variation-report/norvir-h-c-127-p45-0037-epar-assessment-report_en.pdf)

Norvir : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (148.7 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/steps-after-cutoff/norvir-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Norvir : EPAR - Scientific discussion

English (EN) (286.69 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/scientific-discussion/norvir-epar-scientific-discussion_en.pdf)

Norvir : EPAR - Procedural steps taken before authorisation

English (EN) (122.77 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/procedural-steps/norvir-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Norvir

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 September 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-september-2025) 19/09/2025

[Updated advice on body fat changes and lactic acidosis with HIV medicines](/en/news/updated-advice-body-fat-changes-lactic-acidosis-hiv-medicines) 23/10/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 October 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-october-2015) 23/10/2015

#### More information on Norvir

- [A Randomized, Open Label, Phase 4 Study Evaluating the Renal Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF or other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir plus Emtricitabine/Tenofovir DF or Efavirenz /Emtricitabine/Tenofovir DF) compared to Ritonavir-boosted Atazanavir plus Abacavir/Lamivudine in Antiretroviral Treatment-naïve HIV-1 Infected Adults with eGFR ≥ 70 mL/min - post-authorisation study](https://catalogues.ema.europa.eu/study/24883)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 11/11/2025

## Share this page

[Back to top](#main-content)